I recon the big pharma customer under this deal is Bristol-Myers...

I recon the big pharma customer under this deal is Bristol-Myers Squibb.

Revenue is US$20B+ and they’ve already signed with MedAdvisor for Patient Engagement Programs locally.

https://news.bms.com/press-release/...ibb-reports-fourth-quarter-and-full-year-fi-0

https://www.asx.com.au/asxpdf/20160701/pdf/4388n2trtws5tw.pdf

GSK have similar revenue but they are classified as British.

BMS specialises in four key therapy areas: oncology (cancer), cardiovascular (heart), immunoscience and fibrosis (tissue).

BMS probably sit at 10 in the list of big pharma with US$20B revenue, with Johnson & Johnson, Roche and Pfizer at US$50B+ revenue each.

https://www.proclinical.com/blogs/2019-3/the-top-10-pharmaceutical-companies-in-the-world-2019

MedAdvisor already partner with some of the Top 10 pharma’s today (BMS, Novartis, GSK) so there’s a huge revenue opportunity to offer other patient programs in the US.

https://www.medadvisor.com.au/Partners